2015
DOI: 10.1038/srep12693
|View full text |Cite
|
Sign up to set email alerts
|

Reduction of butyrate- and methane-producing microorganisms in patients with Irritable Bowel Syndrome

Abstract: The pathophysiology of irritable bowel syndrome (IBS) remains unclear. Here we investigated the microbiome of a large cohort of patients to identify specific signatures for IBS subtypes. We examined the microbiome of 113 patients with IBS and 66 healthy controls. A subset of these participants provided two samples one month apart. We analyzed a total of 273 fecal samples, generating more than 20 million 16S rRNA sequences. In patients with IBS, a significantly lower microbial diversity was associated with a lo… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

14
226
1
8

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 269 publications
(249 citation statements)
references
References 44 publications
(72 reference statements)
14
226
1
8
Order By: Relevance
“…For microbiome analysis, we loaded the raw sequences into the QIIME 1.9.1 pipeline and performed the quality filtering analysis as previously described42. After filtering, from 33 fecal samples, we obtained a total of 496761 of high-quality sequences with a number of reads ranging from 1435 to 40735 per sample.…”
Section: Methodsmentioning
confidence: 99%
“…For microbiome analysis, we loaded the raw sequences into the QIIME 1.9.1 pipeline and performed the quality filtering analysis as previously described42. After filtering, from 33 fecal samples, we obtained a total of 496761 of high-quality sequences with a number of reads ranging from 1435 to 40735 per sample.…”
Section: Methodsmentioning
confidence: 99%
“…Several groups have identified an altered microbial community, as an additional and potentially central factor, in the feces of patients with IBS. The most notable patient population was those individuals with IBS characterized by diarrhea (Figure ). These patients clearly have a distinct microbial population, characterized by reduced microbial diversity, reduced butyrate‐producing organisms (a metabolite that enhances gut barrier function), and reduced methane producers (which dispose of gas) .…”
Section: Evidence From Human Trials: Absent Evolving or Conclusive?mentioning
confidence: 99%
“…The most notable patient population was those individuals with IBS characterized by diarrhea (Figure ). These patients clearly have a distinct microbial population, characterized by reduced microbial diversity, reduced butyrate‐producing organisms (a metabolite that enhances gut barrier function), and reduced methane producers (which dispose of gas) . These observations make IBS a notable disease for targeted microbial manipulation.…”
Section: Evidence From Human Trials: Absent Evolving or Conclusive?mentioning
confidence: 99%
“…Рифаксимин необратимо связывается с бета-субъединицей ДНК-зависимой РНК полимеразы, что приводит к ингибированию синтеза РНК и белков бакте-рий, способствуя снижению патогенной кишечной бакте-риальной нагрузки [60]. Данный механизм действия особенно актуален при СРК-Д, так как при этом феноти-пе заболевания отмечаются достоверные альтерации кишечного микробиома, заключающиеся в количествен-ном снижении семейств Ruminococcaceae, Erysipelotrichaceae, Methanobacteriaceae и повышении условно-патогенных микроорганизмов, обладающих газопроду-цирующими свойствами [61,62]. В одном из последних метаанализов, включившем в себя 32 исследования (1331 пациент), было показано, что применение рифак-симина приводит к разрешению синдрома избыточного бактериального роста в 72,9% (95% ДИ: 65,5-79,8) [63].…”
Section: заболевания кишечникаunclassified